ENZYVANT
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

ENZYVANT Trademark

Serial Number: 88330079 • Registration: 6072404

ENZYVANT is a trademark filed by Enzyvant Therapeutics GmbH on March 7, 2019. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Enzyvant Therapeutics GmbH (11 trademarks)

Viaduktstrasse 8
Basel 4051 , CH

Entity Type: 99

Trademark Details

Filing Date

March 7, 2019

Registration Date

June 9, 2020

Published for Opposition

March 24, 2020

Goods & Services

Pharmaceutical preparations for human use for the treatment of rare or metabolic, acid ceramidase deficiency, pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; pharmaceutical preparations for human use, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes for the treatment of rare or metabolic, acid ceramidase deficiency, pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto; biologic preparations for medical and therapeutic purposes, namely, tissue-based regenerative therapy to treat pediatric congenital athymia and thymus gland diseases, disorders and conditions, and immune deficiency related thereto

Providing health and medical information; providing information relating to the diagnostic, prophylactic and therapeutic properties of pharmaceutical preparations and biologic preparations for the prevention and treatment of diseases, disorders and conditions

Scientific and technological services, namely, medical research, scientific research and analysis in the fields of pharmaceuticals and biomedicine; pharmaceutical, biomedical and biological therapeutic research services; scientific research in the fields of pharmaceutical and biologic therapeutic preparations, clinical trials and post-market clinical trials; pharmaceutical research and development; providing scientific research information in the fields of pharmaceuticals, biomedicine, clinical trials and post-market clinical trials

Filing History

COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jun 9, 2025 REM1
REGISTERED-PRINCIPAL REGISTER
Jun 9, 2020 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 24, 2020 NPUB
PUBLISHED FOR OPPOSITION
Mar 24, 2020 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 4, 2020 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 19, 2020 PREV
ASSIGNED TO LIE
Feb 10, 2020 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2020 CNSA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 31, 2020 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 31, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 27, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 26, 2020 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jan 26, 2020 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 25, 2020 GNFN
FINAL REFUSAL E-MAILED
Jan 25, 2020 GNFR
FINAL REFUSAL WRITTEN
Jan 25, 2020 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 14, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 13, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 13, 2019 TROA
ASSIGNED TO EXAMINER
Jul 25, 2019 DOCK
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 18, 2019 GNRN
NON-FINAL ACTION E-MAILED
May 18, 2019 GNRT
NON-FINAL ACTION WRITTEN
May 18, 2019 CNRT
ASSIGNED TO EXAMINER
May 9, 2019 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 27, 2019 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 26, 2019 NWOS
NEW APPLICATION ENTERED
Mar 11, 2019 NWAP